Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues.

doi:10.1016/s0046-8177(96)90164-1

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues.

Human pathology - 1 Jun 1996

Wertz I E, Deitch A D, Gumerlock P H, Gandour-Edwards R, Chi S G, de Vere White R W

Abstract excerpt

The prognostic value of the p53 gene (TP53), the most commonly mutated gene in human cancers, has been well established for several cancer types. However, because varying frequencies of TP53 mutations have been identified in prostatic adenocarcinoma (CaP) by genetic and immunohistochemical (IHC) studies, the role of TP53 in CaP tumorigenesis is currently unresolved. These experimental discrepancies could be...

Topics

Adenocarcinoma
Antibodies, Monoclonal
Antigens, Neoplasm
Genes, p53
Humans
Immunohistochemistry
Male
Mutation
Prostatic Diseases
Prostatic Hyperplasia
Prostatic Neoplasms
Staining and Labeling
Tumor Suppressor Protein p53

Source

Open in PubMed

Identifiers

PMID: 8666367
DOI: 10.1016/s0046-8177(96)90164-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics